

Department: Investigation	Segment: All
Circular No: MSE/ID/10702/2021	Date : July 26, 2021

Subject: In the matter of Regenix Drugs Limited

To All Members,

This is with reference to Exchange circular no. MCX-SX/ID/2341/2014 dated November 11, 2014, regarding SEBI order no. WTM/RKA/SRO/131/2014 dated November 10, 2014 in the matter of Regenix Drugs Ltd.

Subsequently, SAT vide order dated April 10, 2017 Hon'ble Securities Appellate Tribunal (SAT), in the appeal pending before it, accorded its approval for the settlement terms approved by HPAC of SEBI on the Settlement application made by the company and its Directors. The SAT order also notes that the appellants (Regenix Drugs Limited and its Directors) have also complied with the terms of settlement, inter alia, by paying Rs. 35,20,000/- towards the settlement charges and Rs. 9,17,640/- towards cost of legal expenses. Pursuant to the terms of Settlement appellants have also opened an escrow account remitting an amount of Rs. 93,70,653/- in Axis Bank.

SEBI now vide email dated July 26, 2021 has advised to remove the names of the following entities w.r.t. SEBI order dated November 10, 2014 from the list of debarred entities:

Sr.No.	Name of Entities
1	Regenix Drugs Limited
2	Mr. Ayyavu Ramamurthy
3	Mr. Vishwas Vasant Pathak
4	Mr. Raju Gunasekaran
5	Ms. Malathy Ramamurthy
6	Mr. Arvind Devanathan
7	Mr. Govindarajan Venkatakrishna
8	Mr. Natarajan Arun

Members of the Exchange are advised to take note of the above and ensure compliance.

For and on behalf of
Metropolitan Stock Exchange of India Limited

Shalini Rebeiro
Assistant Vice President

Metropolitan Stock Exchange of India Limited